What is the first step in managing a patient who presents with widely metastatic (stage III) testicular cancer?

Management of Testicular Cancer with Widespread Metastases

The first step is radical inguinal orchiectomy to obtain histologic diagnosis, followed immediately by cisplatin-based combination chemotherapy (BEP regimen), with the critical exception that in life-threatening metastatic disease with markedly elevated tumor markers, chemotherapy should be initiated immediately based on clinical presentation and markers alone, with orchiectomy delayed until after chemotherapy completion. 1, 2

Pre-Treatment Essential Steps

Tumor Marker Assessment

• Draw serum tumor markers (AFP, β-HCG, LDH) before any intervention, as these are mandatory for IGCCCG risk stratification that directly determines chemotherapy intensity (good prognosis receives 3 cycles BEP, intermediate/poor prognosis receives 4 cycles BEP). 1, 3
• Repeat markers 7 days post-orchiectomy to assess half-life kinetics (AFP half-life should be <7 days, β-HCG <3 days). 2, 3

Fertility Preservation

• Offer sperm cryopreservation before orchiectomy or chemotherapy, as this is the most cost-effective fertility preservation strategy and chemotherapy causes significant gonadal toxicity. 1, 2

Staging Workload for Metastatic Disease

Mandatory Imaging

• CT chest, abdomen, and pelvis with contrast is required to define extent of metastatic disease. 1, 3
• Brain MRI (or CT if MRI unavailable) is mandatory in poor-prognosis patients, particularly with choriocarcinoma/β-HCG >10,000 IU/L, or multiple lung metastases. 1, 2, 3
• Bone scan if alkaline phosphatase is elevated or bone symptoms present. 1, 2, 3

Baseline Laboratory Assessment

• Complete blood count, renal function (creatinine, BUN, creatinine clearance), electrolytes (magnesium, sodium, potassium, calcium), and liver function tests before chemotherapy initiation. 2, 3

Surgical Management

Radical Inguinal Orchiectomy

• Perform radical orchiectomy through inguinal incision with resection of spermatic cord at the internal inguinal ring—never use scrotal approach as this increases local recurrence risk. 1, 2
• Orchiectomy provides definitive histologic diagnosis and is both diagnostic and therapeutic. 2, 4

Critical Exception for Life-Threatening Disease

• In patients with extensive metastases requiring urgent treatment, initiate chemotherapy immediately based on elevated markers and typical clinical presentation without waiting for orchiectomy histology—delay orchiectomy until after chemotherapy completion. 1, 2, 3

IGCCCG Risk Stratification

This classification system determines chemotherapy intensity and must be established before treatment:

Good Prognosis Non-Seminoma (5-year survival 89%)

• Testicular/retroperitoneal primary
• No non-pulmonary visceral metastases
• AFP <1000 ng/mL AND β-HCG <5000 IU/L AND LDH <1.5× ULN
• Treatment: BEP × 3 cycles 1, 3

Intermediate Prognosis Non-Seminoma (5-year survival 78%)

• Testicular/retroperitoneal primary
• No non-pulmonary visceral metastases
• AFP 1000-10,000 ng/mL OR β-HCG 5000-50,000 IU/L OR LDH 1.5-10× ULN
• Treatment: BEP × 4 cycles 1, 3

Poor Prognosis Non-Seminoma (5-year survival 67%)

• Mediastinal primary OR
• Non-pulmonary visceral metastases OR
• AFP >10,000 ng/mL OR β-HCG >50,000 IU/L OR LDH >10× ULN
• Treatment: BEP × 4 cycles 1, 3

Seminoma Risk Groups

• Good prognosis: Any primary site, no non-pulmonary visceral metastases, normal AFP, any β-HCG, any LDH (5-year survival 89%). 1, 3
• Intermediate prognosis: Any primary site, non-pulmonary visceral metastases present, normal AFP, any β-HCG, any LDH (3-year survival 78-93%). 1, 3
• No poor prognosis category exists for pure seminoma. 1

Chemotherapy Administration

BEP Regimen Components

• Bleomycin, Etoposide, and Cisplatin administered in 3-4 cycles depending on IGCCCG risk group. 2, 5

Monitoring During Treatment

• Monitor serum creatinine, BUN, creatinine clearance, and electrolytes (magnesium, sodium, potassium, calcium) before each cycle due to cumulative cisplatin nephrotoxicity. 2

Post-Chemotherapy Management

Response Assessment

• Measure tumor markers and perform repeat CT scans after chemotherapy completion to assess response. 2
• Surgical resection of all residual masses is mandatory when tumor markers normalize, as residual masses may contain viable tumor, teratoma, or necrosis. 2

Critical Pitfalls to Avoid

• Do not delay chemotherapy waiting for orchiectomy in life-threatening metastatic disease—start treatment based on markers and clinical picture. 1, 2
• Do not use scrotal approach for orchiectomy—always use inguinal approach to prevent local recurrence. 1, 2
• Do not skip brain imaging in high-risk patients (β-HCG >10,000 IU/L or >10 lung metastases), as CNS involvement dramatically worsens prognosis. 1, 2
• Post-orchiectomy management must be carried out by highly experienced clinicians at high-volume centers, as treatment complexity requires multidisciplinary expertise. 1

Expected Outcomes

With appropriate treatment, 5-year survival rates are excellent: 99% for stage I, 92% for stage II, and 85% for stage III disease. 2, 4